• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2018, Vol. 20 ›› Issue (1): 7-9.DOI: 10.3969/j.issn.1671-2587.2018.01.003

• 药物性抗体引起免疫性溶血反应专题 • 上一篇    下一篇

微柱凝胶免疫实验检测患者血清中抗肿瘤药物类抗体的临床应用*

刘娟, 陈柄澔, 卢江敏, 郑飞天, 候杜娟, 孟方园, 李翠莹   

  1. 100142 北京,空军总医院输血科
  • 收稿日期:2017-12-11 出版日期:2018-02-20 发布日期:2018-02-28
  • 通讯作者: 李翠莹,女,主要从事临床输血及免疫血液学研究,(E-mail) licuiying2013@qq.com。
  • 作者简介:刘娟(1980-),女,主管技师,博士,主要从事临床输血工作,(Tel)010-66928461(E-mail)juanliu903@163.com。
  • 基金资助:
    *本课题受军区十二五重点项目(No.B14009)资助

Micro-column Gel Immunoassay forDetection ofAntibodies against Anti-tumor Drugs

LIU Juan, CHEN Bing-hao, LU Jiang-Min, et al   

  1. Department of Blood Transfusion,Airforce General Hospital,PLA,Beijing 100142
  • Received:2017-12-11 Online:2018-02-20 Published:2018-02-28

摘要: 目的 检测患者血液中抗肿瘤类药物抗体的产生情况,为临床输血及用药治疗安全性提供依据。方法 随机选取临床长期进行抗肿瘤药物治疗患者的标本309例,分析抗肿瘤药物抗体产生情况。其中检测卡培他滨类药物抗体157例、曲妥珠单抗类抗体152例。分别将患者血清与包被相应药物的O型试剂红细胞,利用微柱凝胶间接抗人球蛋白法,检测患者血清中是否存在抗上述两种抗肿瘤类药物的抗体。结果 在检测的309例血清标本中,共有8例血样检测到抗肿瘤类药物抗体,总体检出率约为2.5%。其中曲妥珠单抗3例,检测率为1.9%,卡培他滨5例,检出率约为3%。结论 患者使用抗肿瘤药物后,体内产生了抗卡培他滨、曲妥珠单抗药物相应的抗体。该类抗体可能会导致免疫性溶血、药物治疗无效等多种免疫性不良反应。为提高临床疗效,避免免疫性溶血反应,在临床开展抗药物抗体检测具有重要意义。

关键词: 抗肿瘤药物抗体, 微柱凝胶法, 免疫性溶血

Abstract: Objective To detect the serumantibodies against oncotherapy agentsand provide clinical datafor safety of transfusion and chemotherapy. Methods A total of 309 serum samples were randomly selected from patients with chemotherapy and antibodies were detected. Antibodies tocapecitabine and trastuzumab were detected in 157 and 152 patients,respectively. The patient's seraweremixed with O-type erythrocytes coated with the corresponding drugs,andthe micro-column gel indirect anti-human globulin method wasperformed to detect the antibodies against the two agents. Results Among 309 serum samples,eight were found to bepositive,with ageneral positive rate of2.5%,including 3 (1.9%) of Trastuzumab and 5 (3%) of capecitabin. Conclusion Detection of the antibodies against anti-tumor chemicals would be necessary toprevent from immune hemolysis and other adverse reactions post-transfusion.

Key words: Antibody, against cancer therapeutic agent, Micro-column gel assay, Immune hemolysis

中图分类号: